These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22901567)

  • 1. Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy.
    Nguyen PL; Chen MH; Zhang Y; Tempany CM; Cormack RA; Beard CJ; Hurwitz MD; Suh WW; D'Amico AV
    J Urol; 2012 Oct; 188(4):1151-6. PubMed ID: 22901567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Prostate Specific Antigen Stability and Predictive Factors of Failure after Permanent Seed Prostate Brachytherapy.
    Tetreault-Laflamme A; Crook J; Hamm J; Pickles T; Keyes M; McKenzie M; Pai H; Bachand F; Morris J
    J Urol; 2018 Jan; 199(1):120-125. PubMed ID: 28827105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the influence of prostate-specific antigen kinetics on metastasis in men with PSA recurrence after partial gland therapy.
    King MT; Nguyen PL; Boldbaatar N; Yang DD; Muralidhar V; Tempany CM; Cormack RA; Hurwitz MD; Suh WW; Pomerantz MM; D'Amico AV; Orio PF
    Brachytherapy; 2019; 18(2):198-203. PubMed ID: 30638910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
    Eggener SE; Roehl KA; Yossepowitch O; Catalona WJ
    J Urol; 2006 Oct; 176(4 Pt 1):1399-403. PubMed ID: 16952643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer.
    Hsu CC; Hsu H; Pickett B; Crehange G; Hsu IC; Dea R; Weinberg V; Gottschalk AR; Kurhanewicz J; Shinohara K; Roach M
    Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):370-7. PubMed ID: 22672747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
    Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing PSA outcome after radical prostatectomy or magnetic resonance imaging-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate.
    D'amico AV; Tempany CM; Schultz D; Cormack RA; Hurwitz M; Beard C; Albert M; Kooy H; Jolesz F; Richie JP
    Urology; 2003 Dec; 62(6):1063-7. PubMed ID: 14665356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate Specific Antigen Criteria to Diagnose Failure of Cancer Control following Focal Therapy of Nonmetastatic Prostate Cancer Using High Intensity Focused Ultrasound.
    Huber PM; Afzal N; Arya M; Boxler S; Dudderidge T; Emberton M; Guillaumier S; Hindley RG; Hosking-Jervis F; Leemann L; Lewi H; McCartan N; Moore CM; Nigam R; Odgen C; Persad R; Thalmann GN; Virdi J; Winkler M; Ahmed HU
    J Urol; 2020 Apr; 203(4):734-742. PubMed ID: 31928408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
    Ko EC; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer.
    Mitchell DM; Swindell R; Elliott T; Wylie JP; Taylor CM; Logue JP
    Radiother Oncol; 2008 Jul; 88(1):102-7. PubMed ID: 18453022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost.
    Jabbari S; Weinberg VK; Shinohara K; Speight JL; Gottschalk AR; Hsu IC; Pickett B; McLaughlin PW; Sandler HM; Roach M
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):36-42. PubMed ID: 19409729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific antigen spikes after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Anderson RL
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):450-6. PubMed ID: 12243821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy.
    Hegde JV; Demanes DJ; Veruttipong D; Raince J; Park SJ; Raman SS; Nickols NG; King CR; Kishan AU; Steinberg ML; Kamrava M
    Brachytherapy; 2017; 16(6):1106-1112. PubMed ID: 28807747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.
    Martinez AA; Kestin LL; Stromberg JS; Gonzalez JA; Wallace M; Gustafson GS; Edmundson GK; Spencer W; Vicini FA
    Int J Radiat Oncol Biol Phys; 2000 May; 47(2):343-52. PubMed ID: 10802358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study.
    Nguyen PL; Chen MH; D'Amico AV; Tempany CM; Steele GS; Albert M; Cormack RA; Carr-Locke DL; Bleday R; Suh WW
    Cancer; 2007 Oct; 110(7):1485-92. PubMed ID: 17701957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for biochemical recurrence after a tissue-ablative prostate-specific antigen <0.2 ng/mL.
    Taussky D; Lambert C; Meissner N; Bahary JP; Delouya G
    Brachytherapy; 2018; 17(5):794-798. PubMed ID: 30153914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcomes of partial prostate treatment with magnetic resonance imaging-guided brachytherapy for patients with favorable-risk prostate cancer.
    King MT; Nguyen PL; Boldbaatar N; Tempany CM; Cormack RA; Beard CJ; Hurwitz MD; Suh WW; D'Amico AV; Orio PF
    Cancer; 2018 Sep; 124(17):3528-3535. PubMed ID: 29975404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
    Kollmeier MA; Stock RG; Stone N
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen (PSA) velocity and benign prostate hypertrophy predict for PSA spikes following prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Lief JH; Hinerman-Mulroy A; Galbreath RW
    Brachytherapy; 2003; 2(3):181-8. PubMed ID: 15062141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.